AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2019: Analysis by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type - ResearchAndMarkets.com

April 16, 2019

DUBLIN--(BUSINESS WIRE)--Apr 16, 2019--The “Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2019 provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 4, 19, 6 and 2 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively.

Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered

1. Introduction

2. Post-Traumatic Stress Disorder (PTSD) - Overview

3. Post-Traumatic Stress Disorder (PTSD) - Therapeutics Development

4. Post-Traumatic Stress Disorder (PTSD) - Therapeutics Assessment

5. Post-Traumatic Stress Disorder (PTSD) - Companies Involved in Therapeutics Development

6. Post-Traumatic Stress Disorder (PTSD) - Drug Profiles

7. Post-Traumatic Stress Disorder (PTSD) - Dormant Projects

8. Post-Traumatic Stress Disorder (PTSD) - Discontinued Products

9. Post-Traumatic Stress Disorder (PTSD) - Product Development Milestones

10. Appendix

Companies Mentioned

  • Actinogen Medical Ltd.
  • Addex Therapeutics Ltd.
  • Amorsa Therapeutics Inc.
  • Anagin Inc.
  • Aptinyx Inc.
  • Armgo Pharma Inc.
  • Artelo Biosciences Inc.
  • Azevan Pharmaceuticals Inc.
  • Catalyst Pharmaceuticals Inc.
  • Chronos Therapeutics Ltd.
  • Corcept Therapeutics Inc.
  • Eli Lilly and Co.
  • Embera NeuroTherapeutics Inc.
  • Immodulon Therapeutics Ltd.
  • Johnson & Johnson
  • Lixte Biotechnology Holdings Inc.
  • NeuroNascent Inc.
  • Omeros Corp.
  • Otsuka Holdings Co. Ltd.
  • Sanofi
  • SpringWorks Therapeutics LLC
  • Tonix Pharmaceuticals Holding Corp.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/xezxrm

View source version on businesswire.com:https://www.businesswire.com/news/home/20190416005514/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Mental Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH MENTAL HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 04/16/2019 07:27 AM/DISC: 04/16/2019 07:26 AM

http://www.businesswire.com/news/home/20190416005514/en